Journal of ethnopharmacology · 2025
Dioscorea polystachya Turcz. Extract attenuates osteoclastogenesis and ovariectomy-induced bone loss in rats.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Juni, Choi Yeojin, Hwang Yeseul, Kim Surim, Hwang Ji Hye, Lee Donghun
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Dioscorea polystachya Turcz. has been traditionally used in East Asian herbal medicine to strengthen bones and treat musculoskeletal conditions. However, the pharmacological mechanisms underlying its anti-osteoporotic effects remain poorly defined.
AIM OF THE STUDY: This study aimed to investigate the anti-osteoporotic potential of D. polystachya root extract (DRE) through its effects on osteoclast differentiation and function, using both in vitro and in vivo models.
MATERIALS AND METHODS: Osteoclastogenesis was induced in bone marrow-derived macrophages (BMMs) by stimulation with receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF), and the effects of DRE on osteoclast formation were assessed by tartrate-resistant acid phosphatase (TRAP) staining and qRT-PCR analysis of key osteoclastogenic genes (e.g., Nfatc1, c-Fos, Ctsk, Mmp9, Acp5). For in vivo analysis, ovariectomized (OVX) rats were orally administered DRE for eight weeks. Micro-computed tomography (micro-CT), histological staining (H&E and IHC for cathepsin K), and serum biomarker assays such as alkaline phosphatase (ALP) and TRAP were used to evaluate trabecular bone preservation and osteoclast activity.
RESULTS: DRE significantly inhibited osteoclast formation and suppressed the expression of osteoclast-related transcription factors and functional markers in vitro. In OVX rats, DRE treatment dose-dependently attenuated trabecular bone loss, reduced serum ALP and TRAP levels, and preserved trabecular architecture. IHC analysis showed a marked reduction in cathepsin K-positive cells in the DRE-treated group compared to OVX controls.
CONCLUSIONS: DRE exerts anti-osteoporotic effects by suppressing osteoclast differentiation and activity, thereby mitigating bone loss in estrogen-deficient conditions. These findings highlight the potential of D. polystachya as a promising natural therapeutic agent for the prevention and treatment of postmenopausal osteoporosis.
AIM OF THE STUDY: This study aimed to investigate the anti-osteoporotic potential of D. polystachya root extract (DRE) through its effects on osteoclast differentiation and function, using both in vitro and in vivo models.
MATERIALS AND METHODS: Osteoclastogenesis was induced in bone marrow-derived macrophages (BMMs) by stimulation with receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF), and the effects of DRE on osteoclast formation were assessed by tartrate-resistant acid phosphatase (TRAP) staining and qRT-PCR analysis of key osteoclastogenic genes (e.g., Nfatc1, c-Fos, Ctsk, Mmp9, Acp5). For in vivo analysis, ovariectomized (OVX) rats were orally administered DRE for eight weeks. Micro-computed tomography (micro-CT), histological staining (H&E and IHC for cathepsin K), and serum biomarker assays such as alkaline phosphatase (ALP) and TRAP were used to evaluate trabecular bone preservation and osteoclast activity.
RESULTS: DRE significantly inhibited osteoclast formation and suppressed the expression of osteoclast-related transcription factors and functional markers in vitro. In OVX rats, DRE treatment dose-dependently attenuated trabecular bone loss, reduced serum ALP and TRAP levels, and preserved trabecular architecture. IHC analysis showed a marked reduction in cathepsin K-positive cells in the DRE-treated group compared to OVX controls.
CONCLUSIONS: DRE exerts anti-osteoporotic effects by suppressing osteoclast differentiation and activity, thereby mitigating bone loss in estrogen-deficient conditions. These findings highlight the potential of D. polystachya as a promising natural therapeutic agent for the prevention and treatment of postmenopausal osteoporosis.